Karyopharm Therapeutics INC ((KPTI)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: The study titled A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) aimed to evaluate the efficacy and safety of selinexor combinations in treating RR DLBCL. This study was significant as it explored new therapeutic combinations for a challenging lymphoma subtype.
Intervention/Treatment: The study tested various combinations of selinexor, an oral drug, with other treatments like rituximab, bendamustine, and polatuzumab vedotin, aiming to enhance treatment efficacy for RR DLBCL.
Study Design: This was an interventional study with a non-randomized, sequential intervention model. It was open-label, meaning no masking was involved, and its primary purpose was treatment-focused.
Study Timeline: The study was first submitted on October 26, 2020, with its last update on September 30, 2025. However, it was withdrawn, indicating it did not proceed as initially planned.
Market Implications: The withdrawal of this study could impact Karyopharm Therapeutics’ stock performance negatively, as it may affect investor confidence. The competitive landscape in lymphoma treatment remains intense, with other companies potentially benefiting from this setback.
The study is currently marked as withdrawn, with further details available on the ClinicalTrials portal.